This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Big Pharma CEOs Indicate More M&A Deals at JP Morgan Meeting
by Zacks Equity Research
Big pharma CEOs hint at spur in M&A activity in 2019 at the 37th J.P. Morgan Healthcare Conference.
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Bristol-Myers, Celgene, Lilly and Glaxo
Novartis' Crizanlizumab Gets Breakthrough Therapy Status
by Zacks Equity Research
Novartis's (NVS) crizanlizumab gets Breakthrough Therapy designation by the FDA for the prevention of VOCs in patients of all genotypes with SCD.
Eli Lilly (LLY) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Eli Lilly (LLY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Lilly Offers $8B to Acquire Cancer-Focused Small Biotech Loxo
by Zacks Equity Research
Lilly (LLY) looks to acquire small cancer biotech, Loxo Oncology, to expand its pipeline into targeted cancer therapies.
Crowded Cancer Space Triggers Big M&A Deals: More in Store?
by Zacks Equity Research
Following two blockbuster merger and acquisition deals, a rise in M&A activity in the pharma space is likely led by consolidation in the cancer space.
Company News For Jan 8, 2019
by Zacks Equity Research
Companies In The News Are: LOXO,LLY,DLTR,PCG,MAT
4 Biotechs That Are Potential Buyouts Post Celgene Deal
by Ekta Bagri
We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2019.
Eli Lilly (LLY) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Eli Lilly (LLY) closed the most recent trading day at $115.28, moving +0.54% from the previous trading session.
Biogen Inks Two Deals to Make Drugs for Neurological Diseases
by Zacks Equity Research
Biogen (BIIB) signs deals with C4 Therapeutics and Skyhawk Therapeutics to develop potential therapies for Alzheimer's disease (AD), Parkinson's disease and other neurological diseases.
Pharma Stock Roundup: BMY to Buy CELG for $74B, MRK Gets Rights to NASH Candidate
by Zacks Equity Research
Bristol-Myers (BMY) is spending $74 billion to buy Celgene. Merck (MRK) exercises option to gain rights to a NASH candidate from partner NGM Biopharmaceuticals.
Nektar, ImaginAb Enter Into Immuno-Oncology Collaboration
by Zacks Equity Research
Nektar (NKTR) and ImaginAb enter into a license and clinical trial collaboration, allowing Nektar to use ImaginAb's immuno-oncology imaging technology.
The Zacks Analyst Blog Highlights: TripAdvisor, Advance Auto, Red Hat, Salesforce and Eli Lily
by Zacks Equity Research
The Zacks Analyst Blog Highlights: TripAdvisor, Advance Auto, Red Hat, Salesforce and Eli Lily
5 Great S&P 500 Stocks to Buy in 2019
by Swarup Gupta
A near-term recession seems unlikely, the job market remains robust and the trade dispute with China could be resolved this year.
Has Eli Lilly and (LLY) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
Teva Stock Rises on Patent Settlement With Neos Therapeutics
by Zacks Equity Research
Teva's (TEVA) shares rally as it enters into an agreement to settle all patent litigation related to its abbreviated new drug application for Neos Therapeutics' ADHD drug, Cotempla XR-ODT.
Forget J&J, Buy These 3 Big Drug Stocks Instead in 2019
by Kinjel Shah
J&J's (JNJ) stock has declined more than 14% since Reuters reported that it knew for decades that its baby powders contained asbestos. It is better to avoid the stock and invest in these three big drug stocks instead.
Bayer (BAYRY) Faces Generic Threat & Rising Competition
by Zacks Equity Research
Bayer (BAYRY) is facing generic threats/competition for many of its products. The genericization of key drugs will negatively impact revenues.
Pfizer Xtandi Succeeds in Late-Stage Prostate Cancer Study
by Zacks Equity Research
Pfizer's (PFE) prostate cancer drug, Xtandi, met the primary endpoint in a late-stage study that can expand the label of the drug to include hormone-sensitive patients.
Pharma Stock Roundup: GSK, PFE Ink Consumer Health JV, JNJ Hit by Talc Allegations
by Zacks Equity Research
Glaxo (GSK) and Pfizer (PFE) agree to merge their consumer healthcare units into a new JV. J&J stock hit by reports alleging it of being aware of the presence of asbestos in baby powder.
Lilly's Shares Rise on Robust 2019 View, Dividend Hike
by Zacks Equity Research
Eli Lilly's (LLY) shares rise 3% on an upbeat outlook for 2019. It also hikes quarterly dividend by 15%.
Allergan Drops, Stops Textured Breast Implant Sales in Europe
by Zacks Equity Research
Allergan (AGN) halts the sale of its textured breast implants and tissue expanders in Europe. Stock declines.
The Zacks Analyst Blog Highlights: Eli Lilly, Mitsubishi UFJ, Thermo Fisher, Oracle and Ecolab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Mitsubishi UFJ, Thermo Fisher, Oracle and Ecolab
Company News For Dec 20, 2018
by Zacks Equity Research
Companies In The News Are: FDX,GIS,LLY,PFE,GSK
Aduro Stock Surges on STING Activator Deal With Eli Lilly
by Zacks Equity Research
Aduro (ADRO) inks a collaboration/license deal with Eli Lilly to develop novel immunotherapies for autoimmune and other inflammatory diseases by leveraging its cGAS-STING inhibitor platform.